PharmaShots | Incisive News in 3 Shots

Subscribe Now

MONALEESA-7

Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer

Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer

November 3, 2020

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

September 22, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us